Search

Learn about MSK's specialty in treating neuroendocrine cancers.

… Friday, March 7, 2025 The good news is that treatments for prostate cancer are helping patients live longer. But an unsettling new challenge is emerging: a different and deadlier form of the cancer called neuroendocrine prostate cancer (NEPC). Researchers at Memorial Sloan Kettering Cancer Center (MSK

A powerful therapy called an antibody-drug conjugate has been approved by the FDA for more people with bladder cancer.

… Thursday, December 11, 2025 A powerful treatment is now an option for many more people with  bladder cancer , the fifth most common form of cancer. The U.S. Food and Drug Administration (FDA) on November 21 approved a combination of two drugs —  enfortumab vedotin (Padcev®)  and an immunotherapy drug

Learn about MSK’s Adolescent and Young Adult program, which is uniquely positioned to help patients like Danielle Leventhal.

… Thursday, October 1, 2020 Tyler Wong’s girlfriend first sensed something was off. In April 2020, the couple was cuddling at home when girlfriend Joanhy felt a lump in Tyler’s belly. Tyler felt it too. Thinking it could be a hernia, Joanhy asked the urologist she works for to examine Tyler. The doctor

For cancer in the liver, interventional radiology techniques can be used to destroy tumors while minimizing damage to healthy liver tissue. 

… Tuesday, April 15, 2025 Treating liver cancer and liver metastases — cancer that has spread to the liver from elsewhere in the body — is challenging. Most patients are not candidates for surgery because there are many tumors or because the tumors are in difficult locations.   In some cases, however,

Learn how Kéara was able to maintain her quality of life after treatment for triple negative breast cancer.

… Monday, April 4, 2022 When Kéara Richardson was diagnosed with triple-negative breast cancer at just 37, she feared her life would never be the same again. But Memorial Sloan Kettering Cancer Center (MSK) offered her an innovative treatment that puts chemotherapy before breast cancer surgery . This approach

Scientists are learning how tumors develop resistance to drugs — and what can be done about it.

… Thursday, July 27, 2017 Summary Drugs targeting a particular mutation in cancer cells can be an effective form of therapy. But the beneficial effects are often short-lived as tumors quickly develop resistance. New research is casting light on how this resistance evolves and what treatment approaches

TV anchor Al Roker discusses his own prostate cancer experiences, disparities in cancer care and outcomes for people of color, the importance of cancer screening for Black men, and more with Dr. Carol Brown, a gynecological oncology surgeon at Memorial Sloan Kettering and Nicholls-Biondi Chair for Health Equity at Memorial Sloan Kettering.

… Friday, February 12, 2021 VIDEO | 05:26 Health Equity and Cancer — A Conversation with Al Roker and Dr. Carol Brown Watch this video to hear NBC's Al Roker and MSK's Dr. Carol Brown discuss health disparities. Video Details When beloved TV anchor Al Roker of NBC News’ TODAY publicly announced that he

Targeting the cancer environment, rather than the cancer itself, could be a new avenue for immunotherapy.

… Wednesday, October 21, 2020 Summary Two MSK-led studies published in the journal Nature support the idea of using immunotherapy drugs to treat the environment surrounding a tumor as an indirect way to combat cancer. Despite the remarkable successes of immune-based treatments for cancer, not everyone

Learn about MSK thoracic surgeon Valerie Rusch and her approach to treating people with lung cancer and other tumors of the chest.

… Wednesday, August 28, 2019 Summary In an interview, MSK thoracic surgeon Valerie Rusch discusses her career path, her commitment to her patients, and her experiences as a woman in a male-dominated field. Valerie Rusch is Vice Chair for Clinical Research in the Department of Surgery at MSK. She is a thoracic

Research shows that TIL therapy, an emerging type of immunotherapy, works in some patients with non-small cell lung cancer.

… Wednesday, May 1, 2024 There is evidence that an emerging type of immunotherapy called TIL therapy may be successful in treating more solid tumors . Research published in Cancer Discovery shows this treatment works in some patients with non-small cell lung cancer . The lead researcher of the multicenter